Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, Carla Colombo et al.|New England Journal of Medicine|2015Cited by 1.6k
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Steven M. Rowe et al.|Thorax|2011Cited by 496
CFTR modulator theratyping: Current status, gaps and future directionsJohn P. Clancy, Katherine L. Tuggle, Calvin U. Cotton et al.|Journal of Cystic Fibrosis|2018Cited by 288